B
Bull
Bull · 25%MDWD
$24.44
Szenariopreis
$12.620
+0.010 (+0.08%)Zum Schluss
Loading chart…
- High
- 12.855
- Open
- 12.850
- VWAP
- 12.69
- Vol
- 108.00K
- Mkt Cap
- 138.14M
- Low
- 12.590
- Amount
- 1.37M
- EV/EBITDA, TTM
- -1.77
Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.
AI analysis of Mediwound Ltd (MDWD)
sellMediwound Ltd is not a good buy right now due to significant financial losses and declining revenues. The current price is $12.66, and the company reported a net loss of $7.4 million in Q2 2026, which is concerning. Additionally, the RSI is at 32.703, indicating that the stock is oversold but may not rebound soon. The forward P/E ratio is high at 34.965, suggesting that the stock is overvalued relative to its earnings potential. The main risk is the company's reliance on government contracts, which has led to a 31.27% year-to-date decline in stock price.
Analyst Ratings (5)
+137.72% upside
Buy
5 Buy
0 Hold
0 Sell
Current: 12.62
Tief
25.00
Durchschnitt
30.00
Hoch
36.00
Alliance Global
Buy
$22
2026-05-28
Alliance Global
2026-05-28
Kursziel
$22
Buy
Oppenheimer
Outperform
$32
2026-05-28
Oppenheimer
2026-05-28
Kursziel
$32
Outperform
H.C. Wainwright
Buy
$36
2025-11-21
H.C. Wainwright
2025-11-21
Kursziel
$36
Buy
Oppenheimer
Outperform
$34
2025-06-02
Oppenheimer
2025-06-02
Kursziel
$34
Outperform
H.C. Wainwright
Buy
$31
2025-05-22
H.C. Wainwright
2025-05-22
Kursziel
$31
Buy
Bewertungskennzahlen
The current forward P/E ratio for Mediwound Ltd (MDWD) is 34.97, compared to its 5-year average forward P/E of -4.00.
Alphio AI Price Scenarios for MDWD
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding MDWD
Event-Zeitleiste
News
9.508-20NASDAQ.COMMediWound Reports Q2 2026 Earnings with Strategic Updates
9.506-29NASDAQ.COMGuardian Pharmacy Shares Surge 8.8% on Strong Investor Sentiment
9.505-28NASDAQ.COMMediWound Reports Q1 2026 Revenue Decline and Reaffirms Guidance
9.505-27Yahoo FinanceMediWound Advances ESCAREX Program Towards Commercialization
2.005-27NASDAQ.COMMediwound Shares Enter Oversold Territory
MDWD FAQ — answered by Alphio AI
Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain. It operates in the Healthcare sector (MEDICINAL CHEMICALS AND BOTANICAL PRODUCTS industry).
Mediwound Ltd is not a good buy right now due to significant financial losses and declining revenues. The current price is $12.66, and the company reported a net loss of $7.4 million in Q2 2026, which is concerning. Additionally, the RSI is at 32.703, indicating that the stock is oversold but may not rebound soon. The forward P/E ratio is high at 34.965, suggesting that the stock is overvalued relative to its earnings potential. The main risk is the company's reliance on government contracts, which has led to a 31.27% year-to-date decline in stock price.
5 analysts cover MDWD: 5 rate it Buy, 0 Hold and 0 Sell. The average price target is 30.00.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.